Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN107,9108,2-1,92
Msft-0,13
Nokia5,8665,921,16
IBM1,10
Mercedes-Benz Group AG57,5857,60,89
PFE0,40
14.02.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026 21:59:32
Cibus Inc Rg (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
2,30 15,58 0,31 462 701
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.02.2026
Popis společnosti
Obecné informace
Název společnostiCibus Inc
TickerCBUS
Kmenové akcie:Ordinary Shares Class A
Kmenové akcie:Ordinary Shares Class B
RICCBUS.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.09.2025
Počet zaměstnanců k 31.12.2024 157
Akcie v oběhu k 29.01.2026 69 597 837
MěnaUSD
Kontaktní informace
Ulice6455 Nancy Ridge Drive
MěstoSAN DIEGO
PSČ92121
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 584 500 008
Fax13026365454

Business Summary: Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cibus Inc revenues decreased 15% to $2.6M. Net loss decreased 58% to $95.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Food Ingredients segment loss decrease of 69% to $75M, United States segment loss decrease of 69% to $75M.
Odvětvová klasifikace
TRBC2012Advanced Medical Equipment & Technology (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Food (Health) Supplement Stores
NAICS2007Research and Development in Biotechnology
NAICS1997Food (Health) Supplement Stores
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 14.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Co-FounderRory Riggs7124.02.202531.05.2023
President, Interim Chief Executive Officer, Co-Founder, Chief Operating Officer, DirectorPeter Beetham6224.02.202531.05.2023
Co-Founder, Executive Vice President, Chief Scientific OfficerGreg Gocal5631.05.202331.05.2023
Chief Financial OfficerCornelis Broos5418.09.202501.10.2024
Senior Vice President - ResearchNoel Sauer5801.01.2024
Chief Legal Officer, General Counsel and Corporate SecretaryJason Stokes5401.01.2024